Shikiar Asset Management Inc. grew its holdings in shares of Urogen Pharma Ltd (NASDAQ:URGN) by 7.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 80,300 shares of the company’s stock after purchasing an additional 5,850 shares during the quarter. Urogen Pharma makes up about 1.2% of Shikiar Asset Management Inc.’s portfolio, making the stock its 23rd biggest holding. Shikiar Asset Management Inc. owned approximately 0.58% of Urogen Pharma worth $2,966,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Parallel Advisors LLC boosted its position in shares of Urogen Pharma by 100.0% during the 4th quarter. Parallel Advisors LLC now owns 1,000 shares of the company’s stock valued at $43,000 after acquiring an additional 500 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in Urogen Pharma by 100.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,000 shares of the company’s stock worth $74,000 after purchasing an additional 1,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Urogen Pharma by 112.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,421 shares of the company’s stock worth $89,000 after purchasing an additional 1,282 shares during the period. Van ECK Associates Corp increased its stake in Urogen Pharma by 27.6% during the fourth quarter. Van ECK Associates Corp now owns 4,364 shares of the company’s stock worth $188,000 after purchasing an additional 944 shares during the period. Finally, JPMorgan Chase & Co. purchased a new stake in Urogen Pharma during the third quarter worth about $320,000. 81.77% of the stock is currently owned by institutional investors.
In other Urogen Pharma news, insider Mark Schoenberg sold 1,991 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $37.30, for a total value of $74,264.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 10.50% of the company’s stock.
A number of analysts have issued reports on the stock. Zacks Investment Research lowered shares of Urogen Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, May 16th. Cowen restated a “buy” rating on shares of Urogen Pharma in a research note on Monday, May 6th. Oppenheimer reaffirmed a “buy” rating on shares of Urogen Pharma in a report on Tuesday, March 19th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $63.00 price target on shares of Urogen Pharma in a report on Tuesday, March 5th. Finally, Raymond James set a $57.00 price target on Urogen Pharma and gave the company a “buy” rating in a report on Friday, March 1st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $64.17.
Shares of Urogen Pharma stock traded down $1.04 during trading hours on Friday, hitting $36.52. 56,900 shares of the company were exchanged, compared to its average volume of 180,520. Urogen Pharma Ltd has a 1 year low of $34.61 and a 1 year high of $61.93. The stock has a market capitalization of $520.87 million, a PE ratio of -7.61 and a beta of 1.33.
Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Thursday, May 9th. The company reported ($1.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.12) by $0.01. Urogen Pharma had a negative return on equity of 61.24% and a negative net margin of 4,296.08%. Sell-side analysts expect that Urogen Pharma Ltd will post -5.41 EPS for the current fiscal year.
About Urogen Pharma
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Featured Story: Percentage Decliners
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.